Oncotype DX Testing in Post-Mastectomy ER/PR Positive, HER2 Negative Breast Cancer

Rationale for Not Performing Oncotype DX Testing

The National Comprehensive Cancer Network (NCCN) guidelines recommend considering the 21-gene assay (Oncotype DX) for patients who are candidates for chemotherapy, which may not apply to this post-mastectomy patient with favorable tumor characteristics 2
In patients who have undergone mastectomy for small (T1c) node-negative tumors, the absolute benefit of adding chemotherapy is already known to be small, making the test less clinically useful in this setting 3, 4
The primary purpose of Oncotype DX testing is to guide decisions about adjuvant chemotherapy in addition to endocrine therapy in patients with early-stage, hormone receptor-positive, HER2-negative breast cancer 1, 2

Oncotype DX provides a Recurrence Score (RS) that stratifies patients into risk categories, with a low risk (RS 0-10) indicating very low risk of distant recurrence with endocrine therapy alone 1
Patients with an intermediate risk (RS 11-25) have limited additional benefit from chemotherapy in postmenopausal women 1, 3
Patients with a high risk (RS ≥31) have a clear benefit from adjuvant chemotherapy 1, 2

T1c (>0.5-2.0 cm), node-negative tumor status suggests relatively favorable prognosis 5, 1
ER and PR positivity indicates likely good response to endocrine therapy alone 2, 4
HER2 negative status eliminates need for anti-HER2 targeted therapy 1, 2
Postmenopausal status (age 63) is associated with less aggressive disease biology in hormone-positive tumors 3, 4
Bilateral mastectomy has already significantly reduced the risk of local recurrence 2

Oncotype DX testing would be more valuable in scenarios where the patient has not yet undergone definitive surgery and treatment decisions are still pending 1, 2
In cases with conflicting clinicopathological features where the benefit of chemotherapy is uncertain 2, 4
For patients with 1-3 positive lymph nodes where the benefit of chemotherapy is questionable 1, 2

For this postmenopausal patient with T1cN0, ER/PR positive, HER2 negative breast cancer who has already undergone bilateral mastectomy, standard endocrine therapy is likely sufficient without the need for Oncotype DX testing to determine chemotherapy benefit 1, 2